Bobby Thomas, Ph.D.

• Research
• Honors & Awards
• Biography
• Publications

Publications

1. Banerjee R, Beal M.F., Thomas B. Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic implications. Trends Neurosci. 2010 Oct 12. [Epub ahead of print].
2. Yin F, Dumont M, Banerjee R, Ma Y, Li H, Lin MT, Beal MF, Nathan C, Thomas B, Ding A. Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. FASEB J. 2010 Jul 28. [Epub ahead of print].
3. Yin F.F., Banerjee R., Thomas B., Zhou P., Qian L., Jia T., Dumont M., Iadecola C., Lin M.T., Beal M.F., Nathan C.F., Ding A. Exaggerated inflammation, impaired host defense and selective neuropathology in progranulin-deficient mice. J. Exp. Med. doi:10.1084/jem.20091568 (2009).
4. Andres-Mateos E., Mejias R., Sasaki M., Li X., Lin B.M., Biskup S., Zhang L., Banerjee R., Thomas B., Yang L., Liu G., Beal M.F., Huso D.L., Dawson T.M., Dawson V.L. Unexpected lack of hypersensitivity in LRRK2 knockout mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neurosci. 29: 15846-15859 (2009).
5.  Daher J. P., Ying M., Banerjee R., McDonald R. S., Dumas Hahn M., Yang L., Beal M. F., Thomas B., Dawson T. M., Moore D.J. Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons. Mol. Neurodegener. 4: 34 (2009).
6. Thomas B. Parkinson’s disease: From molecular pathways in disease to therapeutic approaches. Antiox. Redox Signal. 11: 2077-2082 (2009).
7. Yang L., Calingasan N. Y., Thomas B., Chaturvedi R. K., Kiaei M., Wille E. J., Liby K. T., Williams C., Royce D., Risingsong R., Musiek E. S., Morrow J. D., Sporn M., Beal M. F. Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS One. 4: e5757 (2009).
8. Banerjee R., Starkov A. A., Beal M. F., Thomas B. Mitochondrial dysfunction in the limelight of Parkinson’s disease pathogenesis. BBA Mol Basis Dis. 1792: 651-663 (2009).
9. Sen N., Hara M., Kornberg M. D., Cascio M. B., Bae B. I., Shahani N., Thomas B., Dawson T. M., Dawson V. L., Snyder S. H., Sawa A. Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. Nat. Cell Biol. 10: 866-873 (2008).
10. Habib S. L., Michel D., Masliah E., Thomas B., Ko H. S., Dawson T. M., Abboud H., Clark R. A., Imam S. Z., Role of tuberin in neuronal degeneration. Neurochem Res. 33: 1113-1116 (2008).
11. Thomas B., Beal M. F. “Parkinson’s disease”. Hum. Mol. Gen. 16: R183-194 (2007).
12. Mateos E. A., Perier C., Zhang L., Blanchard-Fillion B., Greco T. M., Thomas B., Ko H. S., Sasaki M., Ischiripoulos H., Przedborski S., Dawson T. M., Dawson V. L. DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc. Natl. Acad. Sci. 104: 14807-14812 (2007).
13. Banerjee R., Saravanan, K.S., Thomas B., Sindhu K. M., Mohanakumar K. P. Evidence for hydroxyl radical scavenging action of nitric oxide donors in the protection against 1-methyl-4-phenyl pyridinium-induced neurotoxicity in rats. Neurochemical Res. 33: 985-995 (2008).
14. Thomas B., Saravanan K.S., Mohanakumar K.P. In vitro and in vivo evidences that antioxidant action contributes to the neuroprotective effects of the neuronal nitric oxide synthase and monoamine oxidase-B inhibitor, 7-nitroindazole. Neurochem Intl. 52: 990-1001 (2008).
15. Thomas B., von Coelln R., Mandir A.S., Trinkaus D.L., Farah M., Lim K. L., Beal M.F., Dawson V. L., Dawson T. M. MPTP and DSP-4 susceptibility of substanta nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity. Neurobiol. Dis. 26: 312-322 (2007).
16.  *von Coelln R., *Thomas B., Andrabi S. A., Lim K. L., Savitt J. M., Saffary R., Andrabi S. A., Stirling W., Bruno K., Hess E. J., Lee M. K., Dawson V. L., Dawson T. M. Inclusion body formation and neurodegeneration are parkin independent in a mouse model of a- synucleinopathy. J Neurosci. 26: 3685-3695 (2006). *Equal contribution (Co-first authors of the article).
17. Hara M., Thomas B., Cascio M. B., Bae B. I., Hester L. D., Dawson V. L., Dawson T. M., Sawa A., Snyder S. H. Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc. Natl. Acad. Sci. USA. 103: 3887-3889 (2006).
18. Wang C., Ko H. S., Thomas B., Tsang F., Shiam-Peng T., Chew K. C. M., Michelle H. L. M., Lim T. M., Soong T. W., Dawson T. M., Lim K. L. Stress induced alterations in parkin solubility promotes parkin aggregation and compromises parkin’s protective function. Hum. Mol. Gen. 14: 3885-3897 (2005).
19. Zhang L*., Shimoji M. S*., Thomas B., Yu S. W., Moore D. J., Marupudi N. I., Torp R., Ottersen O. P., Dawson T. M., Dawson V. L. Mitochondrial localization of the Parkinson’s disease associated protein DJ-1: Implications for pathogenesis. Hum Mol. Gen. 14: 2063-2073 (2005).
20. von Coelln R., Thomas B., Savitt J. M., Lim K. L., Sasaki M., Hess E. J., Dawson V. L., Dawson T. M. Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc. Natl. Acad. Sci. USA. 101: 10744-10749 (2004).
21. Chung K. K. K., Thomas B., Li X., Pletnikova O., Troncoso J. C., Marsh L., Dawson V. L., Dawson T. M. S-nitrosylation of parkin regulates ubiquitination and compromises parkin’s protective function. Science 304: 1328-1331 (2004).
22. Thomas B., Mohanakumar K. P. Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigrostriatum. J Pineal Res. 36: 25-32 (2004).
23. Muralikrishnan D., Thomas B., Mohanakumar K. P. Oxidative stress as a cause of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson’s disease in mice. J Cell & Tissue Res. 3: 1-8 (2003).
24. Mohanakumar K. P., Thomas B., Sharma S. M., Muralikrishnan D., Chowdhury R., Chiueh C. C. Nitric oxide: an antioxidant and neuroprotector. Ann. N.Y. Acad. Sci., 962: 389- 401 (2002).
25. Mehta H., Thomas B., Mohanakumar K. P. Effects of p-chlorophenylalanine on striatal acetylcholinesterase activity and on biogenic amine levels in raphe, tuberculum olfactorium and caudate-putamen during physostigmine-induced tremor in rats. Neurosci. Lett. 299: 105-108, (2001).
26. Usha R., Muralikrishnan D., Thomas B., Ghosh S., Mandal C. N., Mohanakumar K. P. Region specific attenuation of a trypsin like protease in substantia nigra following dopaminergic neurotoxicity by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res. 882: 191-195 (2000).
27. Mohanakumar K. P., Muralikrishnan D., Thomas B. Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Brain Res. 864:281-290, (2000).
28. Sarkar S., Thomas B., Muralikrishnan D., Mohanakumar K. P. Effects of serotoninergic drugs on tremor induced by physostigmine. Behav. Brain Res. 109: 167-193 (2000).
29. Thomas B., Muralikrishnan D., Mohanakumar K. P. In vivo hydroxyl radical generation in the striatum following systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Brain Res. 852: 221-224 (2000).